NGScientists in the United States have reported encouraging results from a personalized cancer vaccine called intismeran autogene, developed by Moderna and Merck. The vaccine targets high-risk melanoma patients who have undergone surgery but remain at risk of recurrence. According to Merck, the treatment, combined with Merck’s immunotherapy drug Keytruda, reduced the risk of cancer returning or death by 49% and the risk of metastasis or death by 59% in a Phase 2b trial involving over 1,000 patients. The vaccine works by using a customized mRNA sequence based on the patient’s tumor mutations to train the immune system to attack cancer cells specifically. Experts have praised the findings as a significant advancement in cancer treatment, highlighting the potential of mRNA technology in oncology.
Bias read (Center): The article presents scientific findings and expert opinions without overt ideological framing. While the development of the vaccine has implications for healthcare policy and public health, the focus remains on medical research and clinical outcomes rather than partisan debate. The tone is balanced
